TOVX news

Theriva Biologics announced the dosing of the first patient in the VIRAGE2 trial to evaluate more frequent dosing of VCN-01 in first-line metastatic pancreatic cancer, following positive data from its previous Phase 2b study.

Theriva Biologics obtained regulatory authorization from the Spanish Agency for the VIRAGE2 clinical trial testing increased VCN-01 dosing in metastatic pancreatic cancer. This study aims to optimize dosing frequency based on previous survival data.

Theriva Biologics published Phase 1 clinical trial results demonstrating that VCN-01 oncolytic adenovirus combined with durvalumab produced prolonged overall survival in heavily pre-treated, immunotherapy-refractory head and neck cancer patients. The data supports VCN-01's stroma-degrading mechanism…